What We’re Reading: Licensing COVID-19 Pill; Pig-to-Human Transplants; Blood Tube Shortage
January 20th 2022Drug makers sign on to help produce Merck’s COVID-19 pill for developing countries; research shows promise for organ transplants from genetically modified pigs; blood sample collection tubes added to FDA list of shortages.
CYNK-101 Receives Fast Track Designation for HER2-Positive Gastric/GEJ Cancers
January 18th 2022Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.
Lack of Monitoring Among Older Patients With CML Linked to Poor TKI Adherence
January 8th 2022The findings showing that older patients with chronic myeloid leukemia (CML) had poor adherence to tyrosine kinase inhibitors (TKIs) was presented last month during the American Society of Hematology Meeting & Exposition.
Hortobagyi Discusses MONALEESA-2 and the Importance of Overall Survival in Breast Cancer Care
January 6th 2022In a career spanning 45 years, Gabriel N. Hortobagyi, MD, has seen the number of cancer therapies increase from 8-10 for all of oncology to more than 400. Here, he discusses the importance of overall survival in breast cancer as seen in the MONALEESA-2 trial.